

Source

Mouse monoclonal antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with Cetuximab F(ab)2.

Isotype

IgG1/kappa

Specificity

Recognizes Cetuximab specifically, no cross reactivity with other humanized antibodies.

Purity

>95% as determined by SDS-PAGE.

Formulation

Lyophilized from 0.22 µm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage


For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

- 4-8°C for 12 months in lyophilized state;
- -70°C for 3 years under sterile conditions after reconstitution.


SDS-PAGE



Anti-Cetuximab Antibody (AY29) on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.


Bioactivity-Elisa

Anti-Cetuximab Antibodies—PK Assay




Detection of cetuximab by bridging ELISA in serum. Immobilized Anti-Cetuximab Antibodies (Cat. No. CEB-Y29) at 2 μg/mL, add increasing concentrations of cetuximab (10% human serum) and then add Biotinylated Anti-Cetuximab Antibodies (Cat. No. CEB-BY31) at 1 μg/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 12 ng/mL.

Determination of Anti-Cetuximab Antibodies Specificity



Demonstration of the specificity of Anti-Cetuximab Antibodies (Cat. No. CEB-Y29) to the cetuximab.

Anti-Cetuximab Antibodies—Inhibition ELISA



Measured by its neutralizing ability in a functional ELISA. Immobilized cetuximab at 2 μg/mL (100 μL/well) can bind pre-mixed Anti-Cetuximab Antibodies (Cat. No. CEB-Y29) and Biotinylated Human EGFRvIII, His Tag (Cat. No. EGR-H82E0) with a inhibition rate of 95%.

Background

Cetuximab is an epidermal growth factor receptor binding FAB. Cetuximab is composed of the Fv (variable; antigen-binding) regions of the 225 murine EGFR monoclonal antibody specific for the N-terminal portion of human EGFR with human IgG1 heavy and kappa light chain constant (framework) regions.

Clinical and Translational Updates

Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.